DiscoverRetina Synthesis
Retina Synthesis
Claim Ownership

Retina Synthesis

Author: Retina Synthesis

Subscribed: 25Played: 645
Share

Description

Retina Synthesis is a data-focused resource exploring therapies in development for retinal diseases.
207 Episodes
Reverse
Nisha Acharya joins Carmen Puliafito to discuss the MEERKAT and SANDCAT Phase 3 trials of vamikibart, an intravitreal anti–IL-6 antibody for uveitic macular edema. She walks through the week-16 primary endpoint — met at both doses in MEERKAT, while in SANDCAT the 1 mg arm missed and the 0.25 mg result stands as nominally significant — the striking durability after just four monthly doses, the large retinal-thickness reductions, and why the FDA's acceptance of the BLA on the totality of the ev...
Ehsan Rahimy joins Carmen Puliafito to discuss the PRIMA photovoltaic retinal implant for advanced geographic atrophy. In PRIMAvera, average prosthetic acuity gains grew from about 25 letters at 12 months to about 30 at 36 months, and 84 percent of patients could read letters and words at home. Rahimy reviews the 36-month safety record — most events clustered in the first six months, with no chronic inflammation on post-mortem histology — patient selection, the roughly 63 hours of postoperati...
Use of anti-VEGF agents in the perioperative period in patients undergoing non-ophthalmic incisional surgery was not associated with increased surgical complications. Our guest is Dr. Odette Houghton of the Mayo Clinic, Scottsdale, Arizona.
Margaret A. Chang, MD, MS, Senior Partner at Retinal Consultants Medical Group in Sacramento, joins hosts Carmen Puliafito and Charles Wykoff to discuss GLOW2, Kodiak's second Phase 3 trial of tarcocimab in diabetic retinopathy. Using the enhanced formulation — 4 mg antibody-biopolymer conjugate plus 1 mg free antibody — GLOW2 enrolled moderately severe to severe NPDR plus mild PDR and mild DME, dosed just five times in a year with all patients on six-month intervals. Chang covers the 62.5% t...
Dr. Arshad M. Khanani, Managing Partner and Director of Clinical Research at Sierra Eye Associates, discusses ELAAVATE, his investigator-sponsored Phase 2 trial of subretinal surabgene lomparvovec (sura-vec) — the first subretinal gene therapy tested in center-involved diabetic macular edema. In nine surgeries, treatment burden fell 70.5% at the low dose and 79.1% at the high dose, with vision maintained or improved and no new safety signals. He addresses bleb-site pigmentary changes, catarac...
loading
Comments